DiaCarta, Inc., a pioneer in molecular diagnostic test development for cancer and infectious diseases, based in California, today announced that it has established a strategic collaboration with OncoAssure Ltd, an Irish medical diagnostics company headquartered at NovaUCD in Dublin.
Oral semaglutide shows promising results for type 2 diabetes in routine clinical settings
Semaglutide and its effects on glycemic control, body weight (BW), and tolerability in routine clinical practice.